Copyright: © 2024 The Author(s). Published by Elsevier Ltd.

IV iron dextran is most cost-effective, yielding 19.26 QALYs compared with 19.10 QALYs for oral ferrous sulfate ...

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in systemic lupus erythematosus.

The updated guideline addresses rapid advances in pharmacologic management, balancing use of newer, older drugs.

In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked ...

Solutions Market growth is driven by rising hospitalization rates, increasing prevalence of chronic diseases, expanding surgical volumes, and growing demand for parenteral nutrition and fluid ...